New approaches to the design and discovery of therapies to prevent erectile dysfunction

Expert Opinion on Drug Discovery

Volumn 9, Issue 12, 2014, Pages 1447-1469

  Toque, Haroldo A ^a   Caldwell, Robert William ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Arginase; Cavernosal smooth muscle relaxation; Erectile dysfunction; Nitric oxide; Penile erection

Indexed keywords

ARGINASE; ARGININE; CITRULLINE; INDUCIBLE NITRIC OXIDE SYNTHASE; MELANOCORTIN RECEPTOR AGONIST; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RHO KINASE; SUPEROXIDE DISMUTASE; VASCULOTROPIN;

AGING; ANDROGEN THERAPY; ARTICLE; CELL THERAPY; CONSERVATIVE TREATMENT; DIABETES MELLITUS; DRUG DESIGN; ERECTILE DYSFUNCTION; GENE THERAPY; HUMAN; HYPERTENSION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PENIS ERECTION; SMOKING; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ARGINASE; ARGININE; DRUG DISCOVERY; ERECTILE DYSFUNCTION; HUMANS; MALE; PENILE ERECTION;

EID: 84912028581     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.949234     Document Type: Article

References (198)

1. Albersen M, Mwamukonda KB, Shindel AW, et al. Evaluation and treatment of erectile dysfunction. Med Clin North Am 2011;95(1):201-12
2. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84(1):50-6
3. Bivalacqua TJ, Usta MF, Champion HC, et al. Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J Androl 2003;24(6 Suppl):S17-37
4. Shamloul R, Ghanem H. Erectile dysfunction. Lancet 2013;381(9861):153-65
5. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 2005;96(3):257-80
6. Manabe K, Heaton JP, Morales A, et al. Pre-penile arteries are dominant in the regulation of penile vascular resistance in the rat. Int J Impot Res 2000;12(3):183-9
7. Sattar AA, Salpigides G, Vanderhaeghen JJ, et al. Cavernous oxygen tension and smooth muscle fibers: relation and function. J Urol 1995;154(5):1736-9
8. Hafez ES, Hafez SD. Erectile dysfunction: anatomical parameters, etiology, diagnosis, and therapy. Arch Androl 2005;51(1):15-31
9. Giuliano F, Rampin O. Neural control of erection. Physiol Behav 2004;83(2):189-201
10. Padma-Nathan H, Christ G, Adaikan G, et al. Pharmacotherapy for erectile dysfunction. J Sex Med 2004;1(2):128-40
11. Melis MR, Succu S, Sanna F, et al. PIP3EA and PD-168077, two selective dopamine D4 receptor agonists, induce penile erection in male rats: site and mechanism of action in the brain. Eur J Neurosci 2006;24(7):2021-30
12. Cowart M, Latshaw SP, Bhatia P, et al. Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. J Med Chem 2004;47(15):3853-64
13. Andersson KE. Pharmacology of penile erection. Pharmacol Rev 2001;53(3):417-50
14. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am 2005;32(4):379-95, v
15. Toda N, Ayajiki K, Okamura T. Nitric oxide and penile erectile function. Pharmacol Ther 2005;106(2):233-66
16. Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Role of nitric oxide and endothelium-derived hyperpolarizing factor (EDHF) in the regulation of blood pressure by leptin in lean and obese rats. Life Sci 2006;79(1):63-71
17. Masuda H. Significance of nitric oxide and its modulation mechanisms by endogenous nitric oxide synthase inhibitors and arginase in the micturition Disorders and erectile dysfunction. Int J Urol 2008;15(2):128-34
18. Jiang DJ, Jia SJ, Yan J, et al. Involvement of DDAH/ADMA/NOS pathway in nicotine-induced endothelial dysfunction. Biochem Biophys Res Commun 2006;349(2):683-93
19. Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in Diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002;106(8):987-92
20. Masuda H, Azuma H. [Biological and pathophysiological roles of endogenous methylarginines as inhibitors of nitric oxide synthase]. Nihon Yakurigaku Zasshi 2002;119(1):29-35
21. Park K, Lee DG, Kim SW, et al. Dimethylarginine dimethylaminohydrolase in rat penile tissue: reduced enzyme activity is responsible for erectile dysfunction in a rat model of atherosclerosis. Int J Impot Res 2009;21(4):228-34
22. Zhang X, Gao J, Liu J, et al. Distribution and factors associated with four premature ejaculation syndromes in outpatients complaining of ejaculating prematurely. J Sex Med 2013;10(6):1603-11
23. Nicolosi A, Glasser DB, Kim SC, et al. Sexual behavior and dysfunction and help-seeking patterns in adults aged 40-80 years in the urban population of Asian countries. BJU Int 2005;95(4):609-14
24. Lochlainn MN, Kenny RA. Sexual activity and aging. J Am Med Dir Assoc 2013;14(8):565-72
25. Stranne J, Malmsten UG, Areskoug B, et al. Influence of age and changes over time on erectile dysfunction: results from two large cross-sectional surveys 11 years apart. Scand J Urol 2013;47(3):198-205
26. Capogrosso P, Colicchia M, Ventimiglia E, et al. One patient out of four with newly diagnosed erectile dysfunction is a young man-worrisome picture from the everyday clinical practice. J Sex Med 2013;10(7):1833-41
27. Hakim L, Van Der Aa F, Bivalacqua TJ, et al. Emerging tools for erectile dysfunction: a role for regenerative medicine. Nat Rev Urol 2012;9(9):520-36
28. Montorsi P, Ravagnani PM, Galli S, et al. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol 2005;96(12B):19M-23M
29. Miner M, Nehra A, Jackson G, et al. All men with vasculogenic erectile dysfunction require a cardiovascular workup. Am J Med 2014;127(3):174-82
30. Montorsi F, Adaikan G, Becher E, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2010;7(11):3572-88
31. Porst H, Burnett A, Brock G, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med 2013;10(1):130-71
32. Chen J, Sofer M, Kaver I, et al. Concomitant use of sildenafil and a vacuum entrapment device for the treatment of erectile dysfunction. J Urol 2004;171(1):292-5
33. Limoge JP, Olins E, Henderson D, et al. Minimally invasive therapies in the treatment of erectile dysfunction in anticoagulated cases: a study of satisfaction and safety. J Urol 1996;155(4):1276-9
34. Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010;57(5):804-14
35. Zhang X, Zang N, Wei Y, et al. Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling. Am J Physiol Endocrinol Metab 2012;302(2):E243-53
36. Buvat J, Maggi M, Guay A, et al. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med 2013;10(1):245-84
37. Argiolas A, Melis MR, Murgia S, et al. ACTH- And alpha-MSH-induced grooming, stretching, yawning and penile erection in male rats: site of action in the brain and role of melanocortin receptors. Brain Res Bull 2000;51(5):425-31
38. Lindblom J, Schioth HB, Larsson A, et al. Autoradiographic discrimination of melanocortin receptors indicates that the MC3 subtype dominates in the medial rat brain. Brain Res 1998;810(1-2):161-71
39. Rosen RC, Diamond LE, Earle DC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res 2004;16(2):135-42
40. Chaussy C, Brendel W, Schmiedt E. Extracorporeally induced destruction of kidney stones by shock waves. Lancet 1980;2(8207):1265-8
41. Bara T, Synder M. Nine-years experience with the use of shock waves for treatment of bone union Disturbances. Ortop Traumatol Rehabil 2007;9(3):254-8
42. Tandan M, Reddy DN, Santosh D, et al. Extracorporeal shock wave lithotripsy of large difficult common bile duct stones: efficacy and analysis of factors that favor stone fragmentation. J Gastroenterol Hepatol 2009;24(8):1370-4
43. Wang CJ, Wang FS, Yang KD, et al. Shock wave therapy induces neovascularization at the tendon-bone junction. A study in rabbits. J Orthop Res 2003;21(6):984-9
44. Aicher A, Heeschen C, Sasaki K, et al. Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: a new modality to increase efficacy of cell therapy in chronic hind limb ischemia. Circulation 2006;114(25):2823-30
45. Vardi Y, Appel B, Jacob G, et al. Can low-intensity extracorporeal shockwave therapy improve erectile function?. A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol 2010;58(2):243-8
46. Goertz O, Lauer H, Hirsch T, et al. Extracorporeal shock waves improve angiogenesis after full thickness burn. Burns 2012;38(7):1010-18
47. Lei H, Liu J, Li H, et al. Low-intensity shock wave therapy and its application to erectile dysfunction. World J Mens Health 2013;31(3):208-14
48. Liu J, Zhou F, Li GY, et al. Evaluation of the effect of different doses of low energy shock wave therapy on the erectile function of streptozotocin (STZ)-induced diabetic rats. Int J Mol Sci 2013;14(5):10661-73
49. Vardi Y, Appel B, Kilchevsky A, et al. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function?. Short-Term results of a randomized, double-blind, sham controlled study. J Urol 2012;187(5):1769-75
50. Gruenwald I, Appel B, Kitrey ND, et al. Shockwave treatment of erectile dysfunction. Ther Adv Urol 2012;5(2):95-9
51. Palmieri A, Imbimbo C, Creta M, et al. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl 2012;35(2):190-5
52. Gonzalez-Cadavid NF, Rajfer J. Molecular pathophysiology and gene therapy of aging-related erectile dysfunction. Exp Gerontol 2004;39(11-12):1705-12
53. Kay MA. State-of-The-Art gene-based therapies: the road ahead. Nat Rev Genet 2011;12(5):316-28
54. Magee TR, Ferrini M, Garban HJ, et al. Gene therapy of erectile dysfunction in the rat with penile neuronal nitric oxide synthase. Biol Reprod 2002;67(3):1033-41
55. Magee TR, Kovanecz I, Davila HH, et al. Antisense and short hairpin RNA (shRNA) constructs targeting PIN (Protein Inhibitor of NOS) ameliorate aging-related erectile dysfunction in the rat. J Sex Med 2007;4(3):633-43
56. Bivalacqua TJ, Champion HC, Mehta YS, et al. Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat. Int J Impot Res 2000;12(Suppl 3):S8-17
57. Champion HC, Bivalacqua TJ, Greenberg SS, et al. Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOSdeficient mice. Proc Natl Acad Sci USA 2002;99(20):13248-53
58. Bivalacqua TJ, Usta MF, Champion HC, et al. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin Diabetic rats. J Urol 2003;169(5):1911-17
59. Cooney R, Hynes SO, Sharif F, et al. Effect of gene delivery of NOS isoforms on intimal hyperplasia and endothelial regeneration after balloon injury. Gene Ther 2007;14(5):396-404
60. Bivalacqua TJ, Usta MF, Champion HC, et al. Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in Diabetic rats. Int J Impot Res 2004;16(1):21-9
61. Garban H, Marquez D, Magee T, et al. Cloning of rat and human inducible penile nitric oxide synthase. Application for gene therapy of erectile dysfunction. Biol Reprod 1997;56(4):954-63
62. Chancellor MB, Tirney S, Mattes CE, et al. Nitric oxide synthase gene transfer for erectile dysfunction in a rat model. BJU Int 2003;91(7):691-6
63. Fennell JP, Brosnan MJ, Frater AJ, et al. Adenovirus-mediated overexpression of extracellular superoxide dismutase improves endothelial dysfunction in a rat model of hypertension. Gene Ther 2002;9(2):110-17
64. Zanetti M, Sato J, Katusic ZS, et al. Gene transfer of superoxide dismutase isoforms reverses endothelial dysfunction in Diabetic rabbit aorta. Am J Physiol Heart Circ Physiol 2001;280(6):H2516-23
65. Toque HA, Romero MJ, Tostes RC, et al. p38 Mitogen-Activated protein kinase (MAPK) increases arginase activity and contributes to endothelial dysfunction in corpora cavernosa from angiotensin-II-Treated mice. J Sex Med 2010;7(12):3857-67
66. Shukla N, Jones R, Persad R, et al. Effect of sildenafil citrate and a nitric oxide donating sildenafil derivative, NCX 911, on cavernosal relaxation and superoxide formation in hypercholesterolaemic rabbits. Eur J Pharmacol 2005;517(3):224-31
67. Khan MA, Thompson CS, Emsley AM, et al. The interaction of homocysteine and copper markedly inhibits the relaxation of rabbit corpus cavernosum: new risk factors for angiopathic erectile dysfunction?. BJU Int 1999;84(6):720-4
68. Toque HA, Tostes RC, Yao L, et al. Arginase II deletion increases corpora cavernosa relaxation in Diabetic mice. J Sex Med 2011;8(3):722-33
69. Li H, Horke S, Forstermann U. Oxidative stress in vascular disease and its pharmacological prevention. Trends Pharmacol Sci 2013;34(6):313-19
70. Fukai T, Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal 2011;15(6):1583-606
71. Bivalacqua TJ, Armstrong JS, Biggerstaff J, et al. Gene transfer of extracellular SOD to the penis reduces O2-And improves erectile function in aged rats. Am J Physiol 2003;284(4):H1408-21
72. Bivalacqua TJ, Usta MF, Kendirci M, et al. Superoxide anion production in the rat penis impairs erectile function in Diabetes: influence of in vivo extracellular superoxide dismutase gene therapy. J Sex Med 2005;2(2):187-97; discussion 97-8
73. Burchardt T, Burchardt M, Chen MW, et al. Expression of VEGF splice variants 144/145 and 205/206 in adult male tissues. IUBMB Life 1999;48(4):405-8
74. Lin CS, Lue TF. Growth factor therapy and neuronal nitric oxide synthase. Int J Impot Res 2004;16(Suppl 1):S38-9
75. Henry GD, Byrne R, Hunyh TT, et al. Intracavernosal injections of vascular endothelial gro h factor protects endothelial dependent corpora cavernosal smooth muscle relaxation in the hypercholesterolemic rabbit: a preliminary study. Int J Impot Res 2000;12(6):334-9
76. Gholami SS, Rogers R, Chang J, et al. The effect of vascular endothelial growth factor and adeno-Associated virus mediated brain Derived neurotrophic factor on neurogenic and vasculogenic erectile dysfunction induced by hyperlipidemia. J Urol 2003;169(4):1577-81
77. Rogers RS, Graziottin TM, Lin CS, et al. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-Associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res 2003;15(1):26-37
78. Shirai M, Yamanaka M, Shiina H, et al. Vascular endothelial growth factor restores erectile function through modulation of the insulin-like growth factor system and sex hormone receptors in Diabetic rat. Biochem Biophys Res Commun 2006;341(3):755-62
79. Yamanaka M, Shirai M, Shiina H, et al. Vascular endothelial growth factor restores erectile function through inhibition of apoptosis in Diabetic rat penile crura. J Urol 2005;173(1):318-23
80. Ryu JK, Cho CH, Shin HY, et al. Combined angiopoietin-1 and vascular endothelial growth factor gene transfer restores cavernous angiogenesis and erectile function in a rat model of hypercholesterolemia. Mol Ther 2006;13(4):705-15
81. Hedlund P, Aszodi A, Pfeifer A, et al. Erectile dysfunction in cyclic GMPdependent kinase I-deficient mice. Proc Natl Acad Sci USA 2000;97(5):2349-54
82. Chang S, Hypolite JA, Velez M, et al. Downregulation of cGMP-dependent protein kinase-1 activity in the corpus cavernosum smooth muscle of diabetic rabbits. Am J Physiol Regul Integr Comp Physiol 2004;287(4):R950-60
83. Bivalacqua TJ, Kendirci M, Champion HC, et al. Dysregulation of cGMP-dependent protein kinase 1 (PKG-1) impairs erectile function in Diabetic rats: influence of in vivo gene therapy of PKG1alpha. BJU Int 2007;99(6):1488-94
84. Bagnost T, Ma L, da Silva RF, et al. Cardiovascular effects of arginase inhibition in spontaneously hypertensive rats with fully developed hypertension. Cardiovasc Res 2010;87(3):569-77
85. Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ, et al. Increased expression of arginase II in human Diabetic corpus cavernosum: in Diabetic-Associated erectile dysfunction. Biochem Biophys Res Commun 2001;283(4):923-7
86. Demougeot C, Prigent-Tessier A, Bagnost T, et al. Time course of vascular arginase expression and activity in spontaneously hypertensive rats. Life Sci 2007;80(12):1128-34
87. Romero MJ, Platt DH, Tawfik HE, et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 2008;102(1):95-102
88. Bivalacqua TJ, Burnett AL, Hellstrom WJ, et al. Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity: influence of in vivo gene therapy of anti-Arginase. Am J Physiol Heart Circ Physiol 2007;292(3):H1340-51
89. Gur S, Kadowitz PJ, Hellstrom WJ. A review of current progress in gene and stem cell therapy for erectile dysfunction. Expert Opin Biol Ther 2008;8(10):1521-38
90. Grazette LP, Rosenzweig A. Role of apoptosis in heart failure. Heart Fail Clin 2005;1(2):251-61
91. Vaegler M, Lenis AT, Daum L, et al. Stem cell therapy for voiding and erectile dysfunction. Nat Rev Urol 2012;Epub ahead of print
92. Strong TD, Gebska MA, Champion HC, et al. Stem and endothelial progenitor cells in erection biology. Int J Impot Res 2008;20(3):243-54
93. Wessells H, Williams SK. Endothelial cell transplantation into the corpus cavernosum: moving towards cell-based gene therapy. J Urol 1999;162(6):2162-4
94. Song YS, Lee HJ, Park IH, et al. Potential differentiation of human mesenchymal stem cell transplanted in rat corpus cavernosum toward endothelial or smooth muscle cells. Int J Impot Res 2007;19(4):378-85
95. Kim SJ, Park SH, Sung YC, et al. Effect of mesenchymal stem cells associated to matrixen on the erectile function in the rat model with bilateral cavernous nerve crushing injury. Int Braz J Urol 2012;38(6):833-41
96. Deng W, Bivalacqua TJ, Chattergoon NN, et al. Adenoviral gene transfer of eNOS: high-level expression in ex vivo expanded marrow stromal cells. Am J Physiol Cell Physiol 2003;285(5):C1322-9
97. Abdel Aziz MT, El-Haggar S, Mostafa T, et al. Effect of mesenchymal stem cell penile transplantation on erectile signaling of aged rats. Andrologia 2010;42(3):187-92
98. Qiu X, Sun C, Yu W, et al. Combined strategy of mesenchymal stem cell injection with vascular endothelial growth factor gene therapy for the treatment of diabetes-Associated erectile dysfunction. J Androl 2012;33(1):37-44
99. Canguven O, Burnett A. Cavernous nerve injury using rodent animal models. J Sex Med 2008;5(8):1776-85
100. Bahk JY, Jung JH, Han H, et al. Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. Exp Clin Transplant 2010;8(2):150-60
101. Cao Y, Sun Z, Liao L, et al. Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo. Biochem Biophys Res Commun 2005;332(2):370-9
102. Ning H, Liu G, Lin G, et al. Fibroblast growth factor 2 promotes endothelial differentiation of adipose tissue-derived stem cells. J Sex Med 2009;6(4):967-79
103. Bella AJ, Lin G, Cagiannos I, et al. Emerging neuromodulatory molecules for the treatment of neurogenic erectile dysfunction caused by cavernous nerve injury. Asian J Androl 2008;10(1):54-9
104. Garcia MM, Fandel TM, Lin G, et al. Treatment of erectile dysfunction in the obese type 2 diabetic ZDF rat with adipose tissue-derived stem cells. J Sex Med 2010;7(1 Pt 1):89-98
105. Zhou WW, Hu JG, Yang JF, et al. Angiogenic effect of bone marrow mesenchymal stem cells transfected with human VEGF gene on myocardial infarcts in rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006;31(5):763-6; 71
106. Pons J, Huang Y, Arakawa-Hoyt J, et al. VEGF improves survival of mesenchymal stem cells in infarcted hearts. Biochem Biophys Res Commun 2008;376(2):419-22
107. Liu G, Sun X, Bian J, et al. Correction of diabetic erectile dysfunction with adipose derived stem cells modified with the vascular endothelial growth factor gene in a rodent diabetic model. PLoS One 2013;8(8):e72790
108. Jeong HH, Piao S, Ha JN, et al. Combined therapeutic effect of udenafil and adipose-derived stem cell (ADSC)/ brain-derived neurotrophic factor (BDNF)-membrane system in a rat model of cavernous nerve injury. Urology 2013;81(5):1108.e7-14
109. Traish AM, Goldstein I, Kim NN. Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. Eur Urol 2007;52(1):54-70
110. Bozkurt O, Bolat D, Demir O, et al. Erectile function and late-onset hypogonadism symptoms related to lower urinary tract symptom severity in elderly men. Asian J Androl 2013;15(6):785-9
111. Aversa A, Bruzziches R, Francomano D, et al. Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine?. Ther Adv Urol 2009;1(4):179-97
112. Filippi S, Vignozzi L, Morelli A, et al. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med 2009;6(12):3274-88
113. Yassin AA, Haffejee M. Testosterone depot injection in male hypogonadism: a critical appraisal. Clin Interv Aging 2007;2(4):577-90
114. Jockenhovel F, Minnemann T, Schubert M, et al. Comparison of longacting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men. Eur J Endocrinol 2009;160(5):815-19
115. Spitzer M, Bhasin S, Travison TG, et al. Sildenafil increases serum testosterone levels by a direct action on the testes. Andrology 2013;1(6):913-18
116. Corona G, Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol 2010;7(1):46-56
117. Hackett G, Cole N, Bhartia M, et al. Testosterone replacement therapy with long-Acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med 2013;10(6):1612-27
118. Hackett G, Cole N, Bhartia M, et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Int J Clin Pract 2014;68(2):203-15
119. Pye SR, Huhtaniemi IT, Finn JD, et al. Late-onset hypogonadism and mortality in aging men. J Clin Endocrinol Metab 2014;99(4):1357-66
120. Pieper GM, Dondlinger LA. Plasma and vascular tissue arginine are decreased in Diabetes: acute arginine supplementation restores endothelium-dependent relaxation by augmenting cGMP production. J Pharmacol Exp Ther 1997;283(2):684-91
121. Hagenfeldt L, Dahlquist G, Persson B. Plasma amino acids in relation to metabolic control in insulin-dependent diabetic children. Acta Paediatr Scand 1989;78(2):278-82
122. Jobgen W, Meininger CJ, Jobgen SC, et al. Dietary L-Arginine supplementation reduces white fat gain and enhances skeletal muscle and brown fat masses in Diet-induced obese rats. J Nutr 2009;139(2):230-7
123. Alam MA, Kauter K, Withers K, et al. Chronic l-Arginine treatment improves metabolic, cardiovascular and liver complications in Diet-induced obesity in rats. Food Funct 2013;4(1):83-91
124. Chin-Dusting JP, Willems L, Kaye DM. L-Arginine transporters in cardiovascular disease: a novel therapeutic target. Pharmacol Ther 2007;116(3):428-36
125. Morris SM Jr. Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol 2009;157(6):922-30
126. Romero MJ, Platt DH, Caldwell RB, et al. Therapeutic use of citrulline in cardiovascular disease. Cardiovasc Drug Rev 2006;24(3-4):275-90
127. Schwedhelm E, Maas R, Freese R, et al. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and Larginine: impact on nitric oxide metabolism. Br J Clin Pharmacol 2008;65(1):51-9
128. Hotta Y, Shiota A, Kataoka T, et al. Oral l-citrulline supplementation improves erectile function and penile structure in castrated rats. Int J Urol 2014;21(6):608-12
129. Cormio L, De Siati M, Lorusso F, et al. Oral L-citrulline supplementation improves erection hardness in men with mild erectile dysfunction. Urology 2011;77(1):119-22
130. Toque HA, Nunes KP, Yao L, et al. Akita spontaneously type 1 diabetic mice exhibit elevated vascular arginase and impaired vascular endothelial and nitrergic function. PLoS One 2013;8(8):e72277
131. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006;5(8):689-702
132. Brioni JD, Nakane M, Hsieh GC, et al. Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res 2002;14(1):8-14
133. Stasch JP, Hobbs AJ. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp pharmacol 2009(191):277-308
134. Bischoff E, Schramm M, Straub A, et al. BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxidedependent penile erection in vivo. Urology 2003;61(2):464-7
135. Claudino MA, da Silva FH, Monica FZ, et al. Long-Term oral treatment with BAY 41-2272 ameliorates impaired corpus cavernosum relaxations in a nitric oxidedeficient rat model. BJU Int 2011;108(1):116-22
136. Bischoff E, Stasch JP. Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition. Circulation 2004;110(12):e320-1; author reply e-1
137. Teixeira CE, Priviero FB, Webb RC. Effects of 5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl] pyrimidin-4- ylamine (BAY 41-2272) on smooth muscle tone, soluble guanylyl cyclase activity, and NADPH oxidase activity/expression in corpus cavernosum from wild-Type, neuronal, and endothelial nitric-oxide synthase null mice. J Pharmacol Exp Ther 2007;322(3):1093-102
138. Albersen M, Linsen L, Tinel H, et al. Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure. J Sex Med 2013;10(5):1268-77
139. Lasker GF, Pankey EA, Frink TJ, et al. The sGC activator BAY 60-2770 has potent erectile activity in the rat. Am J Physiol Heart Circ Physiol 2013;304(12):H1670-9
140. Chitaley K, Webb RC, Mills TM. RhoA/Rho-kinase: a novel player in the regulation of penile erection. Int J Impot Res 2001;13(2):67-72
141. Jin L, Ying Z, Hilgers RH, et al. Increased RhoA/Rho-kinase signaling mediates spontaneous tone in aorta from angiotensin II-induced hypertensive rats. J Pharmacol Exp Ther 2006;318(1):288-95
142. Zhou Q, Liao JK. Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des 2009;15(27):3108-15
143. Hamid SA, Bower HS, Baxter GF. Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am J Physiol Heart Circ Physiol 2007;292(6):H2598-606
144. Rikitake Y, Kim HH, Huang Z, et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005;36(10):2251-7
145. Sato M, Tani E, Fujikawa H, et al. Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res 2000;87(3):195-200
146. Higashi M, Shimokawa H, Hattori T, et al. Long-Term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 2003;93(8):767-75
147. Bao W, Hu E, Tao L, et al. Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovasc Res 2004;61(3):548-58
148. Jin L, Liu T, Lagoda GA, et al. Elevated RhoA/Rho-kinase activity in the aged rat penis: mechanism for age-Associated erectile dysfunction. Faseb J 2006;20(3):536-8
149. Yao L, Chandra S, Toque HA, et al. Prevention of diabetes-induced arginase activation and vascular dysfunction by Rho kinase (ROCK) knockout. Cardiovasc Res 2013;97(3):509-19
150. Toque HA, Nunes KP, Yao L, et al. Activated Rho kinase mediates diabetesinduced elevation of vascular arginase activation and contributes to impaired corpora cavernosa relaxation: possible involvement of p38 MAPK activation. J Sex Med 2013;10(6):1502-15
151. Rikitake Y, Liao JK. ROCKs as therapeutic targets in cardiovascular diseases. Expert Rev Cardiovasc Ther 2005;3(3):441-51
152. Mills TM, Chitaley K, Lewis RW, et al. Nitric oxide inhibits RhoA/Rho-kinase signaling to cause penile erection. Eur J Pharmacol 2002;439(1-3):173-4
153. Wang H, Eto M, Steers WD, et al. RhoA-mediated Ca2+ sensitization in erectile function. J Biol Chem 2002;277(34):30614-21
154. Wingard CJ, Johnson JA, Holmes A, et al. Improved erectile function after Rho-kinase inhibition in a rat castrate model of erectile dysfunction. Am J Physiol Regul Integr Comp Physiol 2003;284(6):R1572-9
155. Bivalacqua TJ, Champion HC, Usta MF, et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetesassociated erectile dysfunction. Proc Natl Acad Sci USA 2004;101(24):9121-6
156. Rajasekaran M, White S, Baquir A, et al. Rho-kinase inhibition improves erectile function in aging male Brown-Norway rats. J Androl 2005;26(2):182-8
157. Gao BH, Zhao ST, Meng FW, et al. Y-27632 improves the erectile dysfunction with ageing in SD rats through adjusting the imbalance between nNo and the Rho-kinase pathways. Andrologia 2007;39(4):146-50
158. Park K, Kim SW, Rhu KS, et al. Chronic administration of an oral Rho kinase inhibitor prevents the development of vasculogenic erectile dysfunction in a rat model. J Sex Med 2006;3(6):996-1003
159. Chandra S, Romero MJ, Shatanawi A, et al. Oxidative species increase arginase activity in endothelial cells through the RhoA/Rho kinase pathway. Br J Pharmacol 2011;165(2):506-19
160. Shatanawi A, Romero MJ, Iddings JA, et al. Angiotensin II-induced vascular endothelial dysfunction through RhoA/ Rho kinase/p38 mitogen-Activated protein kinase/arginase pathway. Am J Physiol Cell Physiol 2011;300(5):C1181-92
161. Ming XF, Barandier C, Viswambharan H, et al. Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 2004;110(24):3708-14
162. Horowitz S, Binion DG, Nelson VM, et al. Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2007;292(5):G1323-36
163. Zhang J, Shen B, Lin A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol Sci 2007;28(6):286-95
164. Nangle MR, Cotter MA, Cameron NE. Correction of nitrergic neurovascular dysfunction in Diabetic mouse corpus cavernosum by p38 mitogen-Activated protein kinase inhibition. Int J Impot Res 2006;18(3):258-63
165. Lysiak JJ, Nguyen QA, Kirby JL, et al. Ischemia-reperfusion of the murine testis stimulates the expression of proinflammatory cytokines and activation of c-jun N-Terminal kinase in a pathway to E-selectin expression. Biol Reprod 2003;69(1):202-10
166. Sommer F, Klotz T, Steinritz D, et al. MAP kinase 1/2 (Erk 1/2) and serine/ threonine specific protein kinase Akt/ PKB expression and activity in the human corpus cavernosum. Int J Impot Res 2002;14(4):217-25
167. Nunes KP, Toque HA, Caldwell RB, et al. Extracellular signal-regulated kinase (ERK) inhibition Decreases arginase activity and improves corpora cavernosal relaxation in streptozotocin (STZ)-induced diabetic mice. J Sex Med 2011;8(12):3335-44
168. Bernier SG, Haldar S, Michel T. Bradykinin-regulated interactions of the mitogen-Activated protein kinase pathway with the endothelial nitric-oxide synthase. J Biol Chem 2000;275(39):30707-15
169. Carneiro FS, Giachini FR, Lima VV, et al. DOCA-salt treatment enhances responses to endothelin-1 in murine corpus cavernosum. Can J Physiol Pharmacol 2008;86(6):320-8
170. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 1998;336(Pt 1):1-17
171. Bachetti T, Comini L, Francolini G, et al. Arginase pathway in human endothelial cells in pathophysiological conditions. J Mol Cell Cardiol 2004;37(2):515-23
172. Mumenthaler SM, Yu H, Tze S, et al. Expression of arginase II in prostate cancer. Int J Oncol 2008;32(2):357-65
173. Lewis RW, Fugl-Meyer KS, Corona G, et al. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med 2010;7(4 Pt 2):1598-607
174. El-Sakka AI. Erectile dysfunction, depression, and ischemic heart disease: does the existence of one component of this triad necessitate inquiring the other two?. J Sex Med 2011;8(4):937-40
175. Berkowitz DE, White R, Li D, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003;108(16):2000-6
176. Kim JH, Bugaj LJ, Oh YJ, et al. Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. J Appl Physiol (1985) 2009;107(4):1249-57
177. Numao N, Masuda H, Sakai Y, et al. Roles of attenuated neuronal nitric-oxide synthase protein expression and accelerated arginase activity in impairing neurogenic relaxation of corpus cavernosum in aged rabbits. BJU Int 2007;99(6):1495-9
178. Segal R, Hannan JL, Liu X, et al. Chronic oral administration of the arginase inhibitor 2(S)-Amino-6-boronohexanoic acid (ABH) improves erectile function in aged rats. J Androl 2012;33(6):1169-75
179. Chitaley K. Type 1 and Type 2 diabeticerectile dysfunction: same diagnosis (ICD-9), different disease?. J Sex Med 2009;6(Suppl 3):262-8
180. Ponholzer A, Temml C, Mock K, et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 2005;47(1):80-5; discussion 5-6
181. Gatti A, Mandosi E, Fallarino M, et al. Metabolic syndrome and erectile dysfunction among obese non-diabetic subjects. J Endocrinol Invest 2009;32(6):542-5
182. Romero MJ, Iddings JA, Platt DH, et al. Diabetes-induced vascular dysfunction involves arginase I. Am J Physiol Heart Circ Physiol 2012;302(1):H159-66
183. Elms SC, Toque HA, Rojas M, et al. The role of arginase I in Diabetesinduced retinal vascular dysfunction in mouse and rat models of diabetes. Diabetologia 2013;56(3):654-62
184. Cox JD, Kim NN, Traish AM, et al. Arginase-boronic acid complex highlights a physiological role in erectile function. Nat Struct Biol 1999;6(11):1043-7
185. Jelodar G, Razmi N, Gholampour V. Arginase alteration in the reproductive system of alloxan-diabetic dogs. J Reprod Dev 2007;53(2):317-21
186. Luscher TF, Richard V, Tschudi M, et al. Endothelial control of vascular tone in large and small coronary arteries. J Am Coll Cardiol 1990;15(3):519-27
187. Touyz RM, Schiffrin EL. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens 2001;19(7):1245-54
188. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003;111(8):1201-9
189. Lekakis JP, Papathanassiou S, Papaioannou TG, et al. Oral L-Arginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol 2002;86(2-3):317-23
190. Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder?. A study of arterial risk factors in 440 impotent men. Lancet 1985;1(8422):181-4
191. Burchardt M, Burchardt T, Baer L, et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000;164(4):1188-91
192. Mittawae B, El-Nashaar AR, Fouda A, et al. Incidence of erectile dysfunction in 800 hypertensive patients: a multicenter Egyptian national study. Urology 2006;67(3):575-8
193. Rodriguez S, Richert L, Berthelot A. Increased arginase activity in aorta of mineralocorticoid-salt hypertensive rats. Clin Exp Hypertens 2000;22(1):75-85
194. Toque HA, Nunes KP, Rojas M, et al. Arginase 1 mediates increased blood pressure and contributes to vascular endothelial dysfunction in Deoxycorticosterone acetate-salt hypertension. Front Immunol 2013;4:219
195. Kifor I, Williams GH, Vickers MA, et al. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997;157(5):1920-5
196. Becker AJ, Uckert S, Stief CG, et al. Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence. Urology 2001;57(1):193-8
197. Imamura M, Waseda Y, Marinova GV, et al. Alterations of NOS, arginase, and DDAH protein expression in rabbit cavernous tissue after administration of cigarette smoke extract. Am J Physiol Regul Integr Comp Physiol 2007;293(5):R2081-9
198. Kalsi JS, Ralph DJ, Thomas P, et al. A nitric oxide-releasing PDE5 inhibitor relaxes human corpus cavernosum in the absence of endogenous nitric oxide. J Sex Med 2005;2(1):53-7